Zoetis Inc. $ZTS Shares Acquired by Carnegie Investment Counsel

Carnegie Investment Counsel grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 9.6% during the first quarter, Holdings Channel.com reports. The firm owned 333,786 shares of the company’s stock after buying an additional 29,297 shares during the quarter. Carnegie Investment Counsel’s holdings in Zoetis were worth $38,199,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC lifted its stake in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Glenview Trust co grew its position in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Barclays cut their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Stifel Nicolaus decreased their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Finally, Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $123.46.

Zoetis Stock Up 0.5%

Shares of Zoetis stock traded up $0.41 during midday trading on Friday, hitting $75.49. The company’s stock had a trading volume of 5,157,373 shares, compared to its average volume of 6,410,874. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market capitalization of $31.65 billion, a P/E ratio of 12.52, a PEG ratio of 1.18 and a beta of 0.75. The stock has a 50-day simple moving average of $79.96 and a 200-day simple moving average of $107.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.